PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 8

	Complete if Known
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		Balaspiri, L. et al., "Preparation of some DI- and tripeptides containing optically active pipecolic acid as fragments of pipecolic acid-brandykinin analogues," Acta Physica et Chemica (1974) 20(1-2):105-110
RD		Chemical Abstracts, vol 126, no. 13, 25 March 1997, Columbus, OH US abstracts no. 171425s, MIWA, Tetsuo et al. "Prepration of carbapenems as antibacterials" abstract & JP 00 912557 (Takeda Chemical Industires Ltd.) 14 January 1997 & Database CA Online Chemical Abstracts Service, Columbus OH, US, Database Accessession no. 126:171425, compound with RN 187265-36-7 and -37-8.
RD		"DCTD Tumor Repository, a catalog of *in vitro* cell lines and transplantable animal and human tumors," (2003)
RD		DINH, T. et al., "Synthesis, conformational analysis, and evaluation of the multidrug resistance-reversing activity of the triamide and proline analogs of hapalosin," *J. Org. Chem.* (1997) 62:6773-6783
RD		GREENBERGER, L. et al., "α-(3,4-Dimethyoxyphenyl)-3,4-dihydro-6,7-dimethoxy-α-[(4-methylpheynl)thiol]-2(1H)-iso-quinolineheptanenitrile (CL329,753): A novel chemosensitizing agent for P-glycoprotein-mediated resistance with improved biological properties compared with verapamil and cyclosporin A," *Oncology Research* (1996) 8(5):207-218
RD		Greene et al., Protecting Groups in Organic Synthesis, 2nd Ed. Wiley & Sons, Inc. (1991) pg. 5, lines 23-27
RD		Kovacs, G. et al., "Antiamnesic effects of D-pipecolic acid and analogues of Pro-Leu-Gly-NH2 in rats," Pharm. Biochem. Behavior (1989) 31:833-837
RD		LOE, D.W. et al., "Structure-activity studies of verapamil analogs that modulate transport of leukotriene C_4 and reduced glutathione by multidrug resistance protein MRP1," *Biochem. Biophys. Res. Commun.* (2000) 275:795-803
X		Mackie et al., Guidebook to Organic Synthesis, 2nd Ed. Wiley & Sons, Inc. (1991) (BOOK - NOT PROVIDED)

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known	
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		Martin, J., "Enantioselective protonation of amide enolates derived from piperidine-2-carboxylic acid," Tetrahedron Lett. (1997) 38(41):7181-7182
RD		MÁTYUS, P. et al., "Novel pyridazino[4,5-b][1,5]oxazepines and –thiazepines as 5-HT_{1A} receptor ligands," *Bioorg. Med. Chem. Lett.* (1997) 7(22):2857-2862
RD		*Merck Index, The*, 12th Ed., Susan Baduvari, Ed. (1996) Whitehouse Station, New Jersey, Entry #10303
RD		NAKANISHI, O. et al., "Potentiation of the antitumor activity by a novel quinoline compound, MS-209, in multidrug-resistant solid tumor cell lines," *Oncol. Research* (1997) 9:61-69
RD		NARASAKI, F. et al., "A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene," *Cancer Chemother. Pharmacol.* (1997) 40:425-432
RD		NEWMAN, R. et al., "MDL 201,307: A novel benzothiazepine modulator of multiple drug resistance," *J. Exp. Therap. & Oncol.* (1996) 1:109-118
RD		NOGAE, I. et al., "Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein," *Biochem. Pharmacol.* (1989) 38(3):519-527
RD		NORMAN, B., "Inhibitors of MRP1-mediated multidrug resistance," *Drugs of the Future* (1998) 23(9):1001-1013
RD		Norman, B. et al., "Reversal of Resistance in multidrug resistance protein (MRP1)-overexpressing cells by LY329146," Bio. Med. Chem. Let., (1999) 9:3381-3386

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

	Complete if Known
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		OBERLIES, N. et al., "Structure-activity relationships of diverse annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells," *J. Med. Chem.* (1997) 40:2102-2106
RD		O'CONNELL, C. et al., "Synthesis and evaluation of hapalosin and analogs as MDR-reversing agents," *Bioorganic & Medicinal Chem. Letters* (1999) 9:1541-1546
RD		OGINO, J. et al., "Dendroamides, new cyclic hexapeptides from a blue-green alga. Multidrug-resistance reversing activity of dendroamide A," *J. Nat. Prod.* (1996) 59:581-586
RD		Ojima, I. et al., "Designing taxanes to treat multidrug-resistant tumors," Modern Drug Discovery (1999) 45-52
RD		OKUNO, T. et al., "Chemical study on hepalosin, a cyclic depsipeptide possessing multidrug resistance reversing activities: Synthesis, structure and biological activity," *Tetrahedron* (1996) 52(47):14723-14734
RD		PAJEVA, I. et al., "A comparative molecular field analysis of propafenone-type modulators of cancer multidrug resistance," *Quant. Struc.- Act. Relat.* (1998) 17:301-312
RD		PAJEVA, I. et al., "Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: A comparative molecular field analysis study," *J. Med. Chem.* (1998) 41:1815-1826
RD		PAJEVA, I. et al., "QSAR and molecular modelling of catamphiphilic drugs able to modulate multidrug resistance in tumors," *Quant. Struc. – Act. Relat.* (1997) 16:1-10
RD		Patel, N. and Rothenberg, M., "Multidrug resistance in cancer chemotherapy," Investigational New Drugs (1994) 12:1-13

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 8

Complete if Known	
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		PAYEN, L. et al., "Reversal of MRP-mediated multidrug resistance in human lung cancer cells by the antiprogestatin drug RU486," *Biochem. & Biophys. Res. Commun.* (1999) 258:513-518
RD		PEARCE, H. et al., "Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance," *Proc. Natl. Acad. Sci. USA* (1989) 86:5128-5132
RD		PEARCE, H. et al., "Structural characteristics of compounds that modulate P-glycoprotein-associated multidrug resistance," *Adv. In Enzyme Regs.* (1990) 30:357-373
RD		PEREIRA, E. et al., "Reversal of multidrug resistance by verapamil analogues," *Biochem. Pharm.* (1995) 50(4):451-457
RD		PFISTER, J. et al., "Methanodibenzosuberylpiperazines as potent multidrug resistance reversal agents," *Bioorg. & Med. Chem. Letters* (1995) 5(21):2473-2476
RD		POMMERENKE, E. et al., "Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells," *Cancer Letters* (1990) 55:17-23
RD		POURTIER-MANZANEDO, A. et al., "SDZ PSC 833 and SDZ 280-446 are the most active of various resistance-modifying agents in restoring rhodamine-123 retention within multidrug resistant P388 cells," *Anti-Cancer Drugs* (1992) 3:419-425
RD		Prost, S., "Mechanisms of Resistance to Topoisomerases Poisons," Gen. Pharmac. (1995) 26(8):1773-1784
RD		Ramu, A. et al., "Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds," Cancer Chemother Pharmacol (1994) 34:423-430

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				*Complete if Known*	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/996,657
				Filing Date	November 29, 2001
				First Named Inventor	Charles Raymond Degenhardt
				Group Art Unit	1625
(use as many sheets as necessary)				Examiner Name	Rita J. Desai
Sheet	5	of	8	Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		Ramu, A. et al., "Reversal of multidrug resistance by phenothiazines and structurally related compounds," Cancer Chemother Pharmacol (1992) 30:165-173
RD		RAMU, N. et al., "Circumvention of adriamycin resistance dipyridamole analogues: a structure-activity relationship study," *Int. J. Cancer* (1989) 43:487-491
RD		RAO, U. et al., "Direct demonstration of high affinity interactions of immunosuppressant drugs with the drug binding site of the human P-glycoprotein," *Molecular Pharmacology* (1994) 45:773-776
RD		Regina, A. et al., "Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT," J Neurochem (1999) 73(5):1954-1963
RD		RENAU, T. et al., "Chapter 12. Antimicrobial potentiation approaches: targets and inhibitors," *Annual Reports in Medicinal Chemistry* (1998) 33:121-129
RD		Robert, J., "Multidrug resistance in oncology: diagnostic and therapeutic approaches," Eur. J. Clin. Invest. (1999) 29:536-545
RD		ROBERT, J., "Multidrug resistance reversal agents," *Drugs of the Future* (1997) 22(2):149-158
RD		ROBERT, J., "Proposals for concomitant use of several modulators of multidrug resistance in clinics," *Anticancer Research* (1994) 14:2371-2374
RD		ROE, M. et al., "Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives," *Bioorganic & Med. Chem. Letters* (1999) 9:595-600

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Complete if Known	
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		SAEKI, T. et al., "Human P-glycoprotein transports cyclosporin A and FK506," *J. Biol. Chem.* (1993) 268(9):6077-6080
RD		SAFA, A., "Photoaffinity labels for characterizing drug interaction sites of P-glycoprotein," *Methods in Enzymology* (1998) 292:289-307
RD		SANGLARD, D. et al., "Mechanisms of resistance to azole antifungal agents in *candida albicans* isolates from AIDS patients involve specific multidrug transporters," *Antimicrobial Agents & Chemo.* (1995) 39(11):2378-2386
RD		Sarkadi, B. et al., "Expression of the Human Multidrug Resistance cDNA in Insect Cells Generates High Activity Drug-stimulated Membrane ATPase," J. Biological Chemistry (1992) 267(7):4854-4858
RD		SARKADI, B. et al., "Interaction of bioactive hydrophobic peptides with the human multidrug transporter," *FASEB* (1994) 8:766-770
RD		SARKADI, B. et al., "Search for specific inhibitors of multidrug resistance," *Seminars in Cancer Biology* (1997) 8:171-182
RD		SATO, S.-i. et al., "Potentiation of vincristine and antinomycin D by a new synthetic imidazole anti-tumor agent YM534 active against human cancer cells and multidrug-resistant cells," *Anti-Cancer Drug Design* (1989) 4:125-135
RD		SATO, W. et al., "Reversal of multidrug resistance by a novel quinoline derivative, MS-209," *Cancer Chemo. Pharmacol.* (1995) 35:271-277
RD		SATO, Y. et al., "Studies on new β-adrenergic blocking agents. I. Synthesis and pharmacology of coumarin derivatives," *Chem. Pharm. Bulletin* (1972) 20(5):905-917

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 8

	Complete if Known
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		SAWANISHI, H. et al., "Novel inhibitors for multidrug resistance: 1,3,5-triazacycloheptanes," *J. Med. Chem.* (1995) 38:5066-5070
RD		SAWANISHI, H. et al., "Structure-activity relationships of diamines, dicarboxamides, and disulfonamides on vinblastine accumulation in P388/ADR cells," *Chem. Pharm. Bulletin* (1994) 42(7):1459-1462
RD		SCALA, S. et al., "P-glycoprotein substrates and antagonists cluster into two distinct groups," *Mol. Pharm.* (1997) 51:1024-1033
RD		SEELIG, A., "A general pattern for substrate recognition by P-glycoprotein," *Eur. J. Biochem.* (1998) 251:252-261
RD		SEPRODI, J. et al., "Peptide derivatives against multidrug resistance," *Peptides* (1996) 801-802
RD		SHAH, A. et al., "6,12-dihydro-1-benzopyrano [3,4-*b*][1,4] benzothiazin-6-ones: synthesis and *mdr* reversal in tumor cells," *Anticancer Research* (1998) 18:3001-3004
RD		SHAROM, F. et al., "Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation," *Biochem. Journal* (1998) 333:621-630
RD		SHAROM, F. et al., "Spectroscopic and biophysical approaches for studying the structure and function of the P-glycoprotein multidrug transporter," *Biochem. Cell Biol.* (1998) 76:695-708
RD		Stark, H. et al., "Enzyme-catalyzed prodrug approaches for the histamine H3-receptor agonist (R)-α-methylhistamine," Bio. Med. Chem. (2001) 9:191-198

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

Complete if Known	
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RD		*USP Dictionary of USAN and International Drug Names*, U.S. Pharmacopeia, Rockville, Maryland (2001) 2001 Edition, 749
RD		Vicar, J. et al., "Amino acids and peptides. CIX. Synthesis and infrared spectroscopy of 2,5-piperazinediones derived from proline and pipecolic acid," Collect. Czech. Chem. Commun. (1972) 37:4060-4071
RD		Zablocki, J.A. et al., "A Novel Series of Orally Active Antiplatelet Agents," Bio. Med. Chem. (1995) 3(5):539-551

Examiner Signature	RD Desai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

U.S. PATENT DOCUMENTS

Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
RD		4,181,722	Beranger et al.	Jan-80
RD		4,911,923	Wallach	Mar-90
RD		4,963,553	Tseng et al.	Oct-90
RD		5,091,187	Haynes	Feb-92
RD		5,177,077	Hohlweg et al.	Jan-93
RD		5,506,239	Sato et al.	Apr-96
RD		5,665,719	Bock et al.	Sep-97
RD		5,693,767	Klemke et al.	Dec-97
RD		5,736,539	Graham et al.	Apr-98
RD		5,830,915	Pikul et al.	Nov-98
RD		5,834,014	Weiner et al.	Nov-98
RD		6,211,186	McIver et al.	Apr-01
RD		6,221,872	Gangee	Apr-01
RD		6,329,872	Chatterjee	Dec-01
RD		6,376,514	Degenhardt et al.	Apr-02
RD		6,602,884 B2	Bacque et al.	Aug-03
RD		6,803,362	Carruthers et al.	Oct-04
RD		6,806,455	Zarate et al.	Oct-04
RD		6,809,093	Degenhardt et al.	Oct-04
RD		6,815,458	Andersson et al.	Nov-04
RD		6,815,465	Makk et al.	Nov-04
RD		2004/0132722	Degenhardt et al.	Jul-04

Examiner Signature	RDesai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

PTO/SB/08A
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	09/996,657
Filing Date	November 29, 2001
First Named Inventor	Charles Raymond Degenhardt
Group Art Unit	1625
Examiner Name	Rita J. Desai
Attorney Docket Number	010785-9003-02

U.S. PATENT DOCUMENTS

Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS

Examiner Initials		Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
RD		BE	563610	H. Morren	Jun-58		
RD		DE	19548797	Dr. Karl Thomae GmbH	Jul-97		
RD		DE	3524955	Sandroz-Patent-GmbH	Jan-86		
RD		EP	0363212	Mitsui Toatsu Chemicals, Inc.	Nov-90		
RD		FR	2267104	Ferlux-Labo S.A.	Nov-75		
RD		FR	2567885	Sandoz S.A.	Jan-86		
RD		GB	2163150	Sandoz S.A.	Feb-86		
RD		WO	92/18478	Boehringer Mannheim Italia S.P.A.	Oct-92		
RD		WO	93/04042	Otsuka Pharmaceutical Co., Ltd.	Mar-93		
RD		WO	97/26240	Bristol-Myers Squibb Co.	Jul-97		
RD		WO	99/65867	Du Pont Pharmaceuticals Company	Dec-99		
RD		WO	00/37458	Schering Corporation	Jun-00		

Examiner Signature	R Desai	Date Considered	8/11/05

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.